Evaluating the antidiabetic effects of R-verapamil in type 1 and type 2 diabetes mellitus mouse models.
The global incidence of diabetes mellitus (DM) is increasing. Types 1 and 2 DM are associated with declining β-cell function. Verapamil (50% S-verapamil and 50% R-verapamil) can treat DM by downregulating thioredoxin-interacting protein (TXNIP), which induces islet β-cell apoptosis. However, it may...
Guardado en:
Autores principales: | Yu-Syuan Chen, Shao-Ju Weng, Shu-Hsien Chang, Rou-Ying Li, Guang-Tzuu Shane, Jui-Pao Hsu, Sheng-Wen Yeh, Ai-Ching Chang, Meng-Ju Lee |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/76988b25082843899a3702c76d03fa40 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs
por: Olga D. Ostroumova, et al.
Publicado: (2018) -
Complexity of antidiabetic medication regimen is associated with increased diabetes-related distress in persons with type 2 diabetes mellitus
por: Rajesh Garg, et al.
Publicado: (2021) -
Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds
por: Nie X, et al.
Publicado: (2020) -
Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
por: Stefan D. Anker
Publicado: (2019) -
Influence of verapamil on the pharmacokinetics of oridonin in rats
por: Jing Liu, et al.
Publicado: (2019)